Shire might dial up its $30B Baxalta offer, but not without more info

Baxalta ($BXLT) CEO Ludwig Hantson's dismissals of Shire's ($SHPG) $30 billion advance have always left room for the possibility that a bigger offer could get a conversation started. And Shire may consider upping its pitch, but first it needs more details on the financial future of its target, according to reports. More from FiercePharma

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.